Less Ads, More Data, More Tools Register for FREE

Pin to quick picksINS.L Regulatory News (INS)

  • There is currently no data for INS

Contract win

6 Jun 2018 07:00

RNS Number : 4052Q
Instem plc
06 June 2018
 

6 June 2018

Instem plc

("Instem")

 

Contract win

 

Leading Fortune 500 Company adopts Instem's Samarind RMS solution for its worldwide medical products regulatory tracking system

 

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that a leading Fortune 500 medical products and pharmaceuticals company has adopted Instem's Samarind RMS Software-as-a-Service ("SaaS") solution. The contract is worth approximately US$750,000 incorporating both perpetual license and SaaS revenue streams with c. 80% of the contract value being recognised in 2018 and annual recurring revenue of US$169,000.

 

Samarind RMS provides medical device and pharmaceutical companies with a smarter way to manage their Product Information, facilitating initial marketing authorisation and supporting ongoing regulatory compliance. The product is optimised to enable these companies to register and track their regulated products worldwide by maintaining a single integrated database of all relevant information, which is then used to update regulators as products change over time. The comprehensive functionality provided by Samarind RMS enables customers to systematically define and execute complex regulatory activities across a globally dispersed workforce whilst providing a single place to find, analyse and act on a wealth of product and regulatory information.

 

Phil Reason, CEO of Instem plc, said: "This contract win with a global company, which ranks among the top 25 on the Fortune 500, continues the good momentum experienced with our regulatory information management solutions 2017 to date and particularly Instem's success in the medical device field. We are very pleased to be delivering this as a SaaS agreement."

 

For further information, please contact:

 

Instem plc

+44 (0) 1785 825 600

Phil Reason, CEO

 

Nigel Goldsmith, CFO

 

 

 

N+1 Singer (Nominated Adviser & Broker)

+44 (0) 20 7496 3000

Richard Lindley

James White

 

 

 

Walbrook Financial PR

+44 (0) 20 7933 8780

Paul Cornelius

instem@walbrookpr.com

Helen Cresswell

Sam Allen

 

 

 

 

 

About Instem

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management and Data Collection; Regulatory Solutions for Submissions and Compliance; and Informatics-based Insight Generation.

 

Instem solutions are in use by customers worldwide and enable our clients to bring life enhancing products to market faster.

 

Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

 

Instem supports over 500 clients through offices in the United States, United Kingdom, France, Japan, China and India.

 

To learn more about Instem solutions and its mission, please visit instem.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAFKPDKABKDAAK
Date   Source Headline
15th Feb 201811:05 amRNSSecond Price Monitoring Extn
15th Feb 201811:00 amRNSPrice Monitoring Extension
29th Jan 20187:00 amRNSDirector/PDMR Shareholding
23rd Jan 20185:27 pmRNSHolding(s) in Company
16th Jan 20187:01 amRNSContract Win
16th Jan 20187:00 amRNSTrading Statement
5th Oct 201711:30 amRNSHolding(s) in Company
29th Sep 201712:17 pmRNSIssue of Equity & Total Voting Rights
26th Sep 20177:00 amRNSHalf-year Report
21st Sep 20175:57 pmRNSHolding(s) in Company
4th Sep 20177:00 amRNSNotice of Results
31st May 20178:39 amRNSPayment of consideration and total voting rights
19th May 20175:00 pmRNSHolding(s) in Company
18th May 201710:24 amRNSResult of AGM
9th May 20172:25 pmRNSIssue of Equity and Total Voting Rights
28th Apr 20175:12 pmRNSHolding(s) in Company
26th Apr 20177:00 amRNSUS Government Contract
21st Apr 20177:00 amRNSPosting of Annual Report and Notice of AGM
4th Apr 201710:10 amRNSHolding(s) in Company
4th Apr 201710:10 amRNSHolding(s) in Company
29th Mar 20173:46 pmRNSHolding(s) in Company
28th Mar 20177:00 amRNSFinal Results
9th Mar 20177:00 amRNSInvestor Teach-in
7th Mar 20177:00 amRNSNotice of Results
16th Jan 20177:00 amRNSTrading Statement
9th Jan 20172:30 pmRNSAppointment of Chief Operating Officer
9th Jan 20177:00 amRNSGrowth & Innovation Forum
20th Dec 20165:23 pmRNSHolding(s) in Company
19th Dec 20164:58 pmRNSHolding(s) in Company
15th Dec 20167:00 amRNSRevised Earn Out Settlement
21st Nov 20167:00 amRNSTrading Statement
22nd Sep 20167:00 amRNSHolding(s) in Company
21st Sep 20168:08 amRNSIssue of Equity
19th Sep 20167:00 amRNSHalf-year Report
5th Sep 20163:40 pmRNSEarnings Enhancing Acquisition of Notocord®
24th Aug 20167:00 amRNSTrading Update and Notice of Half-Year Results
9th Jun 20165:32 pmRNSIssue of Equity
1st Jun 20161:55 pmRNSHolding(s) in Company
31st May 20167:00 amRNSAcquisition, Issue of Equity & Total Voting Rights
26th May 20165:42 pmRNSResult of AGM
19th May 20162:31 pmRNSHolding(s) in Company
16th May 20164:30 pmRNSIssue of Equity and Total Voting Rights
7th Apr 20169:42 amRNSHolding(s) in Company
5th Apr 20167:00 amRNSFinal Results
4th Apr 20167:00 amRNSFour SEND related contract wins
15th Mar 20167:00 amRNSTwo SEND Submit Contract Wins
14th Mar 20167:00 amRNSNotice of Results
3rd Mar 201610:56 amRNSHolding(s) in Company
29th Feb 20169:56 amRNSHolding(s) in Company (Correction)
26th Feb 20169:26 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.